Pregled bibliografske jedinice broj: 260497
Arylsulfatase A in multiple sclerosis
Arylsulfatase A in multiple sclerosis // Abstracts of the 46th International Neuropsychiatric Congres ; u: Neurologia Croatica. Supplement 55 (2006) (S2) / Barac, B (ur.).
Zagreb, 2006. str. 144-145 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 260497 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Arylsulfatase A in multiple sclerosis
Autori
Bačić Baronica, Koraljka ; Mlinac, Kristina ; Vladić, Anton ; Kalanj-Bognar, Svjetlana
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the 46th International Neuropsychiatric Congres ; u: Neurologia Croatica. Supplement 55 (2006) (S2)
/ Barac, B - Zagreb, 2006, 144-145
Skup
46th International Neuropsychiatric Congres (46 ; 2006)
Mjesto i datum
Pula, Hrvatska, 15.06.2006. - 17.06.2006
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
arylsulfatasa A; multiple sclerosis
Sažetak
The aim of this study was to elucidate possible involvement of a lysosomal enzyme arylsulfatase A (ASA) in complex pathogenesis and clinical features of multiple sclerosis (MS). Low ASA activities have been reported in healthy individuals due to condition termed ASA pseudodeficiency (ASA-PD). Mutations associated with ASA-PD may underlie the susceptibility for neurological disorders. Possible contribution of ASA-PD mutations to pathogenesis of multiple sclerosis is explained by death of oligodendrocyte subpopulations resulting with exposure of myelin antigens and immune reaction.2 For the purposes of this study, blood samples were collected from patients with diagnosis of multiple sclerosis (N=29, 15 females and 14 males ; age range: 22-68 years) and individuals in control group (N=15, 7 females, 8 males ; age range: 20-71 years). The diagnosis of MS was made according to McDonalds criteria3. The ASA activity was measured in leukocyte homogenates by spectrophotometric method using p-nitrocatechol sulfate as chromogenic substrate.4 The presence of previously described mutation associated with ASA-PD (1524+95 A-G mutation) was analyzed in patients and controls, using PCR-RFLP method (polymerase chain reaction– restriction fragment length polymorphism).2 Determination of ASA activity showed slightly lower values in MS patients (105± 44 nmol h-1 mg-1) in comparison with controls (120± 53 nmol h-1 mg-1). A decrease of ASA activity below normal values (60 nmol h-1 mg-1) was found in two patients. Although all other measured ASA activities were in the normal range (60 – 300 nmol h-1 mg-1), a distribution of obtained results showed a trend toward lower values in MS patients. Genotyping for ASA-PD 1524+95 A-G mutation showed that 6 MS patients and 1 control were heterozygous carriers for this mutation. In conclusion, presented preliminary data show that further study on a larger sample is necessary in order to estimate a possible association of MS clinical features with a presence of different mutations in the ASA gene and alterations of ASA activity.
Izvorni jezik
Engleski